New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
10:59 EDTJBL, BBRY, SBGI, OHRP, RHT, MTOR, ARWR, SWHC, PIR, VRTXOptions with decreasing implied volatility
Options with decreasing implied volatility: OHRP VRTX ARWR SBGI PIR MTOR BBRY SWHC RHT JBL
News For OHRP;VRTX;ARWR;SBGI;PIR;MTOR;BBRY;SWHC;RHT;JBL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
March 23, 2015
07:47 EDTVRTXVertex says VX-661, ivacaftor generally well tolerated in 12-week Phase 2 study
Vertex Pharmaceuticals announced data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the F508del mutation. The study evaluated two doses of VX-661 in combination with ivacaftor. The primary endpoint of the study was safety. The study showed that the combination regimen was generally well tolerated, and all patients completed 12 weeks of treatment. The most common adverse events were pulmonary exacerbation, which occurred in 38% of all patients who received VX-661 and 44% of those who received placebo, and cough, which occurred in 33% of all patients who received VX-661 and 39% of those who received placebo. Secondary endpoints evaluated the effect of the combination on lung function, and the mean within-group absolute improvement from baseline in ppFEV1 for those who received 100 mg of VX-661 in combination with ivacafto was 4.4 and 3.0 percentage points at week 4 and through 12 weeks of treatment, respectively. Consistent with prior Phase 2 studies that evaluated 4 weeks of treatment with VX-661 in combination with ivacaftor, this study showed a rapid improvement in lung function within four weeks of treatment, and after patients completed treatment, lung function returned to baseline. These safety and efficacy data, together with other data from multiple previously completed Phase 2 studies of VX-661, support Vertex’s ongoing Phase 3 program of VX-661 in combination with ivacaftor. The Phase 3 program is evaluating VX-661 in combination with ivacaftor and consists of four Phase 3 studies, including a study in people with two copies of the F508del mutation that began enrollment in February. The other three studies will enroll people with CF who have one copy of the F508del mutation and a second mutation that is either a gating mutation, residual function mutation or a mutation that results in minimal CFTR function.
06:04 EDTBBRYStocks with implied volatility above IV index mean; ZIOP BBRY
Subscribe for More Information
March 20, 2015
16:22 EDTPIRGlenhill Advisors reports 5.2% passive stake in Pier 1 Imports
Subscribe for More Information
10:00 EDTPIROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:24 EDTPIROn The Fly: Pre-market Movers
UP AFTER EARNINGS: Ctrip.com (CTRP), up 20.1%... Rally Software (RALY), up 17.3%... Nike (NKE), up 5.2%... Darden Restaurants (DRI), up 4.3%... Cheetah Mobile (CMCM), up 3.6%. ALSO HIGHER: Prothena (PRTA), up 40.2% after reporting positive results from Phase 1 study of PRX002... Viggle (VGGL), up 26.9% after confirming receipt of offer from chairman and CEO Robert Sillerman... Intercept Pharmaceuticals (ICPT), up 8.5% after announcing new data analyses from FLINT trial... Biogen Idec (BIIB), up 9.7% after presenting positive interim results from study of aducanumab... Pier 1 Imports (PIR), up 5.2% after being upgraded to Outperform from Perform at Oppenheimer... JinkoSolar (JKS), up 2.8% after announcing that it will supply 75 MWdc of its PV solar modules to Red Horse 2 project and following a strategic collaboration agreement with DuPont (DD). DuPont is up just under 1%. DOWN AFTER EARNINGS: AK Steel (AKS), down 6.8%... Youku Tudou (YOKU), down 4.9%... Tiffany (TIF), down 3.3%. ALSO LOWER: Macerich (MAC), down 7.7% after Simon makes $95.50 per share "best and final" offer.
06:04 EDTBBRYGlobal smartphone shipments to reach 1.4B units in 2015, DigiTimes Research says
Global smartphone shipments in 2015 is expected to increase 16.4% to reach 1.40B units, reports DigiTimes Research. The shipment growth is due to higher growth in demand in emerging markets including India, Southeast Asia and Latin America. Android (GOOG) will account for 78.5% of 2015 global smartphone shipments, Apple's (AAPL) iOS 16.6%, Microsoft (MSFT) Windows 4% and BlackBerry (BBRY) 0.6%.Reference Link
05:41 EDTPIRPier 1 Imports upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
March 19, 2015
10:02 EDTMTOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:32 EDTRHTRed Hat upgraded to Positive from Mixed at OTR Global
Subscribe for More Information
07:22 EDTBBRYBlackBerry volatility elevated into Q4 and outlook
Blackberry March weekly call option implied volatility is at 85, April is at 66, May is at 58, June is at 54; compared to its 26-week average of 54 according to Track Data, suggesting large April price movement into the expected release of Q4 results on March 27.
05:57 EDTBBRYStocks with implied volatility above IV index mean; BBRY NFLX
Subscribe for More Information
05:50 EDTBBRYMicrosoft, BlackBerry raises cooperation for software products, DigiTimes says
Microsoft and Blackberry have been increasing their cooperation with other companies to promote sales of software platforms and related services, reports DigiTimes. According to industry sources, the new eefforts come after their global smartphone market edge dropped 2.8% and 0.6%, respectively. Reference Link
05:46 EDTMTORMeritor downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Meritor to Equal Weight saying currency headwinds and soft Brazil truck trends put consensus estimates at risk. The firm cut its price target for shares to $15 from $17.
March 18, 2015
18:32 EDTJBLOn The Fly: After Hours Movers
UP AFTER EARNINGS: Guess (GES), up 12.4% after reporting fourth quarter results and guidance... Shoe Carnival (SCVL), up 10%... NQ Mobile (NQ), up 9.1%... Tilly's (TLYS), up 1.3%... Cintas (CTAS), up 1.3% after reporting quarterly results and raising fiscal 2015 guidance. DOWN AFTER EARNINGS: Williams-Sonoma (WSM), down 4.1%... Jabil Circuit (JBL), down 1.8%... Juno Therapeutics (JUNO), down 3.3%. ALSO LOWER: Concert Pharmaceuticals (CNCE), down 4.4% after filing to sell common stock... Tekmira Pharmaceuticals (TKMR), down 3.7% after filing to sell 6M shares of common stock.
16:12 EDTJBLJabil Circuit backs FY15 core EPS view of $1.85-$2.15, consensus $2.03
Subscribe for More Information
16:10 EDTJBLJabil Circuit sees Q3 core EPS 43c-55c, consensus 47c
Subscribe for More Information
16:09 EDTJBLJabil Circuit reports Q2 core EPS 50c, consensus 45c
Subscribe for More Information
15:20 EDTJBLNotable companies reporting after market close
Subscribe for More Information
07:28 EDTJBLJabil Circuit March volatility elevated into Q2 and outlook
Subscribe for More Information
06:01 EDTBBRYStocks with implied volatility above IV index mean; BBRY NFLX
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use